local_hospital

Helse Moere Og Romsdal HF

Address
Aasehaugen 1, 6017 Ålesund, Norway

Cardiovascular and Stroke Research

At Helse Moere Og Romsdal HF, clinical trials in cardiovascular disease and neurology focus on major conditions such as atherosclerotic cardiovascular disease, acute myocardial infarction, atrial fibrillation, stroke, and transthyretin amyloid cardiomyopathy. The studies are designed to test new ways to prevent serious events, improve recovery after vascular injury, and evaluate better treatment options for people at high risk.

  • Stroke prevention after ischemic events and transient ischemic attacks
  • Heart rhythm-related clot prevention in atrial fibrillation
  • New therapies for myocardial infarction and cardiomyopathy

These trials aim to strengthen prevention and long-term care for patients with high-risk cardiovascular and cerebrovascular conditions.

Oncology and Precision Cancer Medicine

The site has a strong oncology portfolio covering breast cancer, lung cancer, melanoma, prostate cancer, testicular cancer, multiple myeloma, and acute myeloid leukemia. Research here explores both standard cancer care and newer approaches such as immunotherapy, targeted treatment selection, and precision medicine for hard-to-treat disease.

  • Immunotherapy for lung cancer and melanoma
  • Targeted cancer treatments matched to tumor biology
  • Precision medicine for rare and advanced cancers

These studies aim to improve survival, reduce relapse, and identify treatments that are better matched to each patient’s cancer profile.

Immune-Mediated and Digestive Diseases

Clinical trials in immune system and digestive disease research include Crohn’s disease, celiac disease, eosinophilic esophagitis, and short bowel syndrome. The work focuses on easing symptoms, maintaining disease control, and testing therapies that may offer better long-term management for chronic inflammatory conditions.

  • Biologic and targeted therapies for Crohn’s disease
  • Symptom relief and healing in celiac disease and eosinophilic esophagitis
  • Supportive treatment for short bowel syndrome

These trials are aimed at improving daily functioning and reducing disease flares in people living with chronic gastrointestinal and immune-mediated disorders.

Neurology, Headache, and Ear Disorders

Research in neurology and related specialties includes studies of multiple sclerosis, chronic migraine, cluster headache, and sudden hearing loss. The clinical trials are evaluating whether new or repurposed treatments can improve symptom control, reduce attacks, and support recovery in conditions that can strongly affect quality of life.

  • Disease-modifying therapy for multiple sclerosis
  • Headache prevention in chronic and episodic cluster headache and migraine
  • Hearing recovery approaches for sudden sensorineural hearing loss

At the Aalesund clinic, this area of research is centered on better symptom management and more effective long-term care for neurological and otologic disorders.

Respiratory, Infectious, and Ear-Nose-Throat Research

Trials in respiratory disease, infectious disease, and ear-nose-throat care involve COPD, lower respiratory tract infection, pneumonia in children, COVID-19, and chronic wet cough. The studies are assessing new ways to reduce exacerbations, improve infection outcomes, and support recovery after acute illness.

  • Exacerbation prevention in COPD
  • Antibiotic effectiveness in childhood respiratory infections
  • Antiviral treatment for acute COVID-19 and long-term complications

This research reflects a practical focus on improving treatment effectiveness and recovery across common respiratory and infectious conditions.

Rheumatology, Dermatology, and Musculoskeletal Care

Trials in rheumatology, dermatology, and musculoskeletal disease address rheumatoid arthritis and psoriasis, with some studies also looking at surgical wound care and inflammation-related outcomes. The research is aimed at finding better strategies to control chronic inflammation, maintain disease remission, and improve treatment convenience.

  • Therapy optimization in rheumatoid arthritis
  • New treatment options for psoriasis
  • Bleeding and wound-healing support in surgical care

These studies combine immune-mediated disease management with efforts to improve everyday treatment experience and clinical outcomes.

Gastroenterology, Endocrine, and Rare Disease Studies

The research portfolio also includes digestive, hormonal, and rare disease trials such as primary adrenal insufficiency, short bowel syndrome, and other complex chronic conditions. These studies are designed to improve symptom control, support long-term disease management, and assess whether newer therapies can offer more reliable benefit.

  • Hormone replacement and quality of life in adrenal insufficiency
  • Long-term support for rare gastrointestinal disorders
  • Improved symptom management in chronic complex disease

At Helse Møre og Romsdal HF, this area highlights care for patients with less common but clinically important chronic diseases.

Site Overview

assignment
43
connected trials
corporate_fare
32
sponsors
science
120
IMPs

Activity Indicator

Last 6 months

3
Trials started
0% vs previous period.
3
Trials started 6–12 months ago
43
Total trials linked
Highly Active
trending_flatStable0%
1
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 14 therapeutic areas and 15 of 120 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 110 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
25
Sponsors (total)
32
Active sponsors
19

Sponsor Network

Top 19 by active trials.

lock +18 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +9 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 112 other sites in Norway

description
Trial volume
43
Outperforms 92% of sites
public
Therapeutic diversity
14areas
Outperforms 91% of sites
groups
Sponsor diversity
32sponsors
Outperforms 92% of sites

Therapeutic Area Benchmark — Norway

Select a therapeutic area to compare against other sites in Norway.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Norway

Market Share

Country: Norway

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Helse Moere Og Romsdal HF

lock Showing 1 of 43 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Multicenter Non-Inferiority Trial Comparing Rituximab and Ocrelizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis Aged 18-60 YearsHelse Bergen HFPhase IIIRecruitingOct 2020

IMP list

lock Showing 1 of 120 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Dexamethasone5Unknown2021-04-012025-04-30

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.